Autopsy report · NCT02999906

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

“For business reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

United Therapeutics

Sponsor type

Industry

Conditions

Pulmonary Arterial Hypertension

Interventions

Oral Treprostinil; Placebo

Participants

0

Trials that died the same way

• RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
  “Business reasons.” (85% match in meaning)
• A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
  “For Strategic Reasons” (79% match in meaning)
• Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
  “Due to business reasons” (77% match in meaning)
• Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.
  “Administrative reasons.” (72% match in meaning)
• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  “Due to financial reasons.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.